Stanley Hsia
Endocrinology, Diabetes & Metabolism · Los Angeles, CANPI 1841300647
Payments from drug & device makers
Across 2,048 payments — averaging $9686.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$11M
- Sanofi US Services Inc.$1.9M
- Modernatx, Inc.$1.7M
- Boehringer Ingelheim$1.2M
- AstraZeneca$690K
- Sanofi Pasteur Inc.$543K
- plus $2.9M from 28 others
Across 84 payments — averaging $6522.22 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$437K
- Eli Lilly$107K
- Corcept Therapeutics$3K
What the payments were for
- Travel & lodging$6,32668%
- Food & beverage$2,90831%
- Education$360%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 204 | $11,014,331 |
| Sanofi US Services Inc. | 112 | $1,853,791 |
| Modernatx, Inc. | 481 | $1,691,866 |
| Boehringer Ingelheim | 52 | $1,156,261 |
| AstraZeneca | 22 | $690,192 |
| Sanofi Pasteur Inc. | 23 | $542,653 |
| Genentech, Inc. | 24 | $376,861 |
| AbbVie(2 entities) | 93 | $366,950 |
| Novartis | 15 | $350,640 |
| Pfizer | 50 | $326,948 |
| Astrazeneca UK Limited | 3 | $283,555 |
| Boehringer Ingelheim International GmbH | 225 | $274,794 |
| Akcea Therapeutics, Inc. | 16 | $158,030 |
| Madrigal Pharmaceuticals | 12 | $144,426 |
| Amgen | 8 | $108,015 |
| Currax Pharmaceuticals LLC | 24 | $103,822 |
| Braintree Laboratories, Inc. | 16 | $99,612 |
| Novo Nordisk AS | 515 | $84,857 |
| GSK | 20 | $64,441 |
| Regeneron | 12 | $38,525 |
| Bayer | 17 | $26,721 |
| Mylan Inc. | 9 | $23,291 |
| Alnylam Pharmaceuticals Inc. | 15 | $20,828 |
| Boehringer Ingelheim RCV GmbH & Co KG | 33 | $11,822 |
| Lexicon Pharmaceuticals, Inc. | 3 | $9,117 |
| Vertex | 2 | $7,201 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 9 | $7,105 |
| Kowa Research Institute, Inc. | 11 | $1,172 |
| Corcept Therapeutics | 5 | $483 |
| Novo Nordisk | 8 | $272 |
| Abbott | 2 | $43 |
| Lilly USA, LLC | 2 | $41 |
| Merck | 1 | $35 |
| Travere Therapeutics, Inc. | 4 | $3 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$19,838,704 in reported general payments places this provider in the 95th percentile of 952 endocrinology, diabetes & metabolism providers in California.
See all endocrinology, diabetes & metabolism providers in California →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 25 | $37,119 |
| JardianceEmpagliflozin | 13 | $20,783 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $3,485 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 11 | $914 |
| Levothyroxine Sodium | 16 | $115 |
| Glimepiride | 14 | $96 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $272 | $37,11925 claims |
| Boehringer IngelheimJardiance | $1,156,261 | $20,78313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 952 endocrinology, diabetes & metabolism providers in California.
Other endocrinology, diabetes & metabolism in Los Angeles
- Shlomo MelmedLos Angeles$3.3M
- Sina TebiLos Angeles$2.4M
- Anthony HeaneyLos Angeles$788K
- Christian GastelumLos Angeles$421K
- Jerrold OlefskySan Diego$26.5M
- Mark ChristiansenWalnut Creek$22.9M
- Timothy BaileyEscondido$22.3M
- Juan FriasSan Diego$14.1M
- Paul NorwoodFresno$6.2M
- Athena Philis-Tsimikasla Jolla$6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.